Definium Therapeutics Announces Positive Clinical Results and Long-Term Cash Runway Through 2030
Definium Therapeutics (DFTX) reported strong third-quarter 2026 financial results, highlighted by a robust cash position of $1.05 billion. This capital is expected to fund operations and commercial preparations for its lead psychiatric drug candidate, DT120, through 2030. The company successfully completed three Phase 3 clinical trials for DT120 targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD). Following these results, Definium plans to submit a New Drug Application (NDA) in the first half of 2027. Additionally, early Phase 2a data for its pipeline candidate DT402 showed positive efficacy signals in adults with autism spectrum disorder. With dual breakthrough therapy designations and an extended financial runway, management is shifting focus toward commercial readiness, including market access and distribution infrastructure to support a potential product launch.

Tickers: $DFTX
Topics: Cash Runway Clinical Trial Results Psychiatric Drugs Regulatory Filing
Read the full article at Motley Fool
Part of the story Definium Therapeutics Announces Positive Clinical Results and Long-Term Cash Runway Through 2030 (4 articles)